Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

VistaGen Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q3, VistaGen Therapeutics's (NASDAQ:VTGN) reported sales totaled $357.90 thousand. Despite a 17.66% increase in earnings, the company posted a loss of $10.54 million. In Q2, VistaGen Therapeutics brought in $358.00 thousand in sales but lost $12.79 million in earnings.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.